Given that SARS-CoV-2 primarily enters the body through the mucosal surfaces of the upper respiratory tract, intranasal (I.N.)vaccination offers a promising alternative by inducing local immune responses, including secretory IgA production, which can provide superior protection against viral transmission and infection [3,4]. The gene discussed is CD79A; the disease is infection.